News|Videos|February 7, 2025
Strategies for Managing Cytopenias and Infection Prophylaxis with CAR-T Therapy
The conversation examines adverse events beyond CRS and neurotoxicities in CAR-T therapy, focusing on strategies for managing prolonged cytopenias, infection prophylaxis, and unique adverse events associated with ide-cel and cilta-cel.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Beyond CRS and neurotoxicities, are there other adverse events that require particular attention?
- How do you address prolonged cytopenias following CAR-T infusion?
- What is your approach to infection prophylaxis and management in these patients?
- Are there any distinct adverse events associated specifically with ide-cel or cilta-cel that clinicians should be aware of?
Advertisement
Related to this article
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
3
Recognizing and Evaluating Diarrhea in Metastatic Triple-Negative Breast Cancer
4
Tumor Grade, Risk Stratification, and Patient Counseling
5